PSC
ZSAN

Piper Sandler & Co’s Zosano Pharma Corporation ZSAN Stock Holding History

Piper Sandler & Co’s Portfolio ZSAN Stock Details ZSAN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-56
Closed -$20K – 20
2017
Q4 		$20K Buy
+56
New +$28.1K 0.02% 10

Other funds holding ZSAN

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
HRCM
Hawk Ridge Capital Management Los Angeles, California $2.75B AUM 20.09% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Piper Sandler & Co's ZSAN Position: Q1 2018 in Review

Piper Sandler & Co sold out of Zosano Pharma Corporation (ZSAN) in Q1 2018, closing a stake of 56 shares — an estimated $20K sold.

Piper Sandler & Co first reported a position in ZSAN in Q4 2017 and held it in 1 quarter. The position peaked at $20K in Q4 2017. 32 funds tracked by Wall St. Rank hold ZSAN as of Q1 2018.

  • Piper Sandler & Co reported no remaining Zosano Pharma Corporation position as of Q1 2018 after selling out during the quarter.
  • Piper Sandler & Co sold 56 Zosano Pharma Corporation shares in Q1 2018, an estimated $20K.
  • Piper Sandler & Co first reported a position in Zosano Pharma Corporation in Q4 2017 and held it in 1 quarter.
  • Piper Sandler & Co's Zosano Pharma Corporation position peaked at $20K in Q4 2017.
  • 32 funds tracked by Wall St. Rank held Zosano Pharma Corporation as of Q1 2018.

Based on Piper Sandler & Co's 13F filing for Q1 2018, filed 15 May 2018.